Introduction to Cellbag Bio-Reactors
The cellbag bioreactors are the reactors used in cell cultivation where cells are grown in presterlised, inflated chambers inorder to improve flexibility, avoid sterlisation and eliminate cleaning process. The reactors are inflated bag that are available in different sizes coupled with different configurations as per the requirement. These reactors are available in both electric as well as rocking base mode. There are sensors attached in order to measure 02 level, maintain pH and have proper concentration of CO2, N2 and additional oxygen. The bioreactors have a number of apllications, for instance, pharmaceuticals, bio productions, R&D and testing with numerous end users.
Market Size and Forecast
Cellbag Bio-Reactor Chamber is anticipated to witness a significant growth during the forecast period, i.e., 2019-2027 owing to increased acceptance of the product by various companies irrespective of their size. The product is widely used in the healthcare industry on the back of reasonable cost and decent return on investment. Additionally, the recent developments and innovations coupled with investment by government and private firms in the sector is anticipated to grow the market demand. The increased requirement for bioreactors in biopharmaceuticals and wide range of applications, for instance, tissue engineering, cell expansion and 3D tissue construction are anticipated to increase the market growth. The overall expansion of healthcare industry with enhanced need for controllable environmental conditions of pH, temperature, shear stress and nutrient supply for cellular constructs and continuous research and developments in order to provide medicines and remedies for autoimmune disorders, organ rejections, cancer and others is indeed anticipated to drive the market growth. The global cellbag bioreactor is segmented by application, by scale and by end user, out of which, the application segment is further segmented into antibody production, virus production, CGMP production, insect cell production, vaccines and others. Out of these, vaccines and antibody production segmented are anticipated to have leading shares in market growth on the back of major developments in vaccines leading to increased innovations and developments in mammalian cell culture techniques. According to data by UNICEF, around 116 million children were immunized against diphtheria, tetanus and pertussis (DTP) in 2018. Despite this, there are still millions of children who have not been immunized yet. With the emergence of new diseases and disorders such as West Nile virus, pathogenic diseases and influenza, the growth of vaccine market has rapidly increased which is further anticipated to improve the cellbag bio reactor market on account of inclination of vaccine industry towards cell based techniques in place of the traditional techniques.
Growth Drivers
New Development and Innovations to Drive the Market Growth
The on-going research and development in the cellbag bioreactors is anticipated to result in the growth of the market. The development of new and advanced bioreactors lead to an increase in their demand. Moreover, the technological advancements in cellbag bioreactor that provide low cost and energy consuming operations which are flexible, have better quality and can be used over large scale are some additional factors estimated to result in improved market growth with increased product demand by the end use industries. The expansion in usage of hybrid bioreactor technology aimed at effective waste management is anticipated to further accelerate the market growth.
Increased Demand To Result in Growth of the Market
With increasing demand for better healthcare facilities, companies are providing better solutions in order to bring about improvements in the medical sector. The rising demand for monoclonal antibodies is a major growth factor owing to its long life, predictable pharmacokinetics, high specificity and low toxicity which has resulted in their high demand. Since monoclonal antibodies are produced inside cellbag bioreactors, this is anticipated to initiate a high growth rate for the market. Additionally, increased demand for cell development, clinical trial manufacturing and process development is anticipated to increase the demand of bioreactors which is further estimated to lead to the growth of cellbag bioreactor chambers market.
Restraints
High cost, problems related to contamination and sterility, issues related to automating the culture process along with volumetric productivity involved in the use of cellbag bio reactors are some significant factors which are anticipated to hamper the growth of this market. Furthermore, the stringent rules & regulations related to the approval of cellbag bioreactors for commercial use is another major factor anticipated to restrict the market growth during the forecast period.
Market Segmentation
Our-in depth analysis of the cellbag bio-reactor chambers market includes the following segments:
By Application Type
- Antibody Production
- Virus Production
- CGMP Production
- Insect Cell Production
- Vaccines
- Others
By Scale Type
- <50L
- 50L-100L
- >100L
By End Users
- Pharmaceutical Companies
- Biopharmaceutical Companies
- Drug Discovery Companies
- Research Institutes
By Region
On the basis of regional analysis, the Mobile App Development market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.
The markets in North America and Europe are anticipated to hold leading shares in the cellbag bioreactor chambers market owing to the huge healthcare industry and recent research and development activities in the region by the enterprises and government biotech firms.The U.S. bioreactor market is anticipated to observe significant growth owing to focus on drug development and improving medical facilities coupled with firms collaborating with medical institutions. The market in Europe is anticipated to witness significant CAGR owing to increased spending on healthcare and presence of industrial participants along with numerous government initiatives in the healthcare sector. The market in Asia-Pacific is anticipated to observe growing shares in the cellbag bioreactor chamber market on the back of unexploited market which results in exploration of new opportunities that are present in the region. The region is anticipated to witness an increase in the number of pharmaceutical companies owing to the various government initiatives and research in this fieled. Additionally, the companies are using advanced technologies to shift towards automatic systems instead of the traditional methods. For instance, rising monoclonal antibiotics and cell culturing which leads to improved use of bioreactors is estimated to improve the market growth.
Get more information on this report: Download Sample PDF
The cellbag bio-reactor chambers market is further classified on the basis of region as follows:
- North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
- Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
- Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
- Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis.
- Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis
Top Featured Companies Dominating the Market
- GE Healthcare
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Merck Millipore
- Thermo Fisher Scientific Inc.
- Startorious Stedim Biotech SA.
- Pall Corporation
- Celltainer
- Finesse
- Kühner AG
- TERUMO BCT, INC.
- Applikon Biotechnology
